Top 5 Prefered Companies To Invest In 2014

Starbucks  (NASDAQ: SBUX  ) dropped as low as 3% in after-market trading upon missing revenue estimates.

For the second fiscal quarter, which ended March 31, Starbucks seemed to do great. It beat Wall Street’s earnings-per-share (EPS) estimates of $0.48 per share with $0.51 per share. However, the Street ultimately punished the stock because it missed revenue expectations. Instead of bringing in $3.59 billion, it raked in $3.56 billion.

Moving beyond those expectations, Starbucks itself was pleased with the results. It was particularly proud of its comparable-store sales, which grew 6%, the 13th consecutive quarter of global comp growth of more than 5%. Over the quarter, Starbucks added 590 new stores worldwide, including 337 Teavana stores.

Meanwhile, the company has worked to cut down on costs. Its operating margin grew 1.8 percentage points to 15.4%.

In a press release, CFO Troy Alstead said, 

Record second quarter results once again illustrate the power of the Starbucks business and brand. Continued strength in our US operations, despite ongoing uncertainty in the macro environment, has fueled our performance and allows us to pursue long term strategic initiatives across our segments. Given our performance in the first half of the year and the considerable momentum in the business as we enter the second-half, we are raising our full year earnings growth target.

Top 5 Prefered Companies To Invest In 2014: BG Group PLC (BRGYY.PK)

BG Group plc (BG Group), incorporated on December 30, 1998, is a natural gas company. The Company is engaged in the exploration, development and production of natural gas and oil. he Company operates in two business segments: Exploration and Production (E&P) and Liquefied Natural Gas (LNG). The Company manages its business on an integrated basis across the Americas, Europe, Africa, Central and South Asia, and Australia. The Company has interests in more than 20 countries on five continents.

Exploration and Production

E&P consists of exploration, development, production and marketing of hydrocarbons with a focus on natural gas. BG Group’s Upstream segment covers exploration and production activities for gas, oil and liquids, plus liquefaction operations associated with integrated LNG projects.

Liquefied Natural Gas

BG Group’s LNG activities combine liquefaction and regasification facilities with the purchasing, shippin g, marketing and sale of LNG. The Company has interest in liquefaction facilities in Egypt and Trinidad and Tobago. BG Group’s LNG Shipping & Marketing segment covers the purchasing, shipping, marketing and sale of LNG, as well as the Group’s interests and capacity in regasification facilities.

Advisors’ Opinion:

  • [By Heather Ingrassia]

    On Thursday, August 15, GasLog (GLOG) announced that it had ordered two new 174K cbm Tri-Fuel Diesel Electric LNG carriers from Samsung Heavy Industries. These carriers are expected to be delivered in 2016 which is the same year the company will begin seven-year charters with BG Group (BRGYY.PK) (BRGXF.PK).

Top 5 Prefered Companies To Invest In 2014: Lexmark International Inc.(LXK)

Lexmark International, Inc., together with its subsidiaries, engages in the development, manufacture, and supply of printing, imaging, document workflow, and content management solutions for offices in North and South America, Europe, the Middle East, Africa, Asia, the Pacific Rim, and the Caribbean. It offers monochrome and color laser printers, laser multifunction products, inkjet all-in-one devices, dot matrix printers, and cartridges and other supplies; and services and solutions, including maintenance, consulting, and systems integration, as well as managed print services, such as asset lifecycle management, implementation and decommissioning services, consumables management, optimization services, and utilization management. The company also provides enterprise content management (ECM) software products, including ImageNow document management, document imaging, and workflow suite that allows users to capture, process, and collaborate on important documents and inform ation, protect data integrity throughout its lifecycle, and access precise content; and industry specific workflow solutions for the healthcare, higher education, government, and financial services industries, as well as for back office functions, including accounting, human resources, contracts, and records. Its software modules include Retention Policy Manager to manage the complete lifecycle of content from creation to destruction or disposition; Business Insight, which integrates IBM Cognos to provide industry and business process dashboards, operational and ad-hoc reporting, and report design tools; workflow software that automates processing steps, simplifies work tasks, and provides real-time monitoring; and eForms module, which enables the online entry and collection of raw data in electronic forms that are accessible from Web sites and portals. The company was founded in 1990 and is headquartered in Lexington, Kentucky.

Advisors’ Opinion:

  • [By Lee Jackson]

    Lexmark International Inc. (NYSE: LXK) is another name that has slowly, but surely, lost its cache as an industry leader. Once one of the premiere names in high-end printers, the company continues to lose market share. It also has very little to offer in terms of innovation and new and exciting products. The stock does pay shareholders a solid 2.9% dividend. The Merrill Lynch price target is $31, and the consensus price target is $31.75. That is far below Friday’s closing price of $41.12.

  • [By Evan Niu, CFA]

    What: Shares of Lexmark (NYSE: LXK  ) have popped today by greater than 17% following the company’s first-quarter earnings release.

    So what: Revenue in the quarter came in at the high end of guidance at $884 million, topping the consensus estimate of $873.6 million. The same is true for Lexmark’s non-GAAP earnings per share of $0.88, which was more than the $0.87 per share adjusted profit that investors were expecting. CEO Paul Rooke said Lexmark continues to transition from a hardware-centric model to a solutions-centric approach, which is underscored by the recent acquisitions of two software companies and the sale of the inkjet business.

  • [By Rich Duprey]

    Printer maker Lexmark (NYSE: LXK  ) announced yesterday its third-quarter dividend of $0.30 per share, the same rate it’s paid for the past five quarters after raising the payout 20% from $0.25 per share.

Top 5 Prefered Companies To Invest In 2014: Rio Tinto Plc(RIO)

Rio Tinto plc engages in finding, mining, and processing mineral resources. The company produces aluminum products, including bauxite, alumina, and aluminum; copper, gold, molybdenum, silver, and nickel; diamonds; minerals, such as borates, titanium dioxide feedstocks, high purity iron, metal powders, zircon, and rutile; thermal and coking coal, and uranium; and iron ore and salt. It primarily operates in Australia, North America, South America, Asia, Europe, and southern Africa. The company was founded in 1873 and is headquartered in London, the United Kingdom. Rio Tinto plc is a subsidiary of Rio Tinto Group.

Advisors’ Opinion:

  • [By Jim Jubak]

    Royal Dutch Shell isn’t alone—companies across the natural resources sector are facing big pressure from shareholders to cut costs and capital spending budgets to make up for falling commodity prices. Iron mining giant Rio Tinto (RIO) reports that it bought $2 billion of Chinese equipment in 2013.

  • [By Rich Duprey]

    Spinning off the assets, which some analysts suggest could be worth as much as $20 billion Australian, gives BHP the chance to shave off those less profitable businesses that it might otherwise have a difficult time selling into a depressed market for those commodities. Rival Rio Tinto (NYSE: RIO  ) has pulled several businesses off the market after hanging out a shingle saying it was willing to sell them, because of a lack of buyers wanting to pay up for what the miner thought they were worth.

  • [By Ben Levisohn]

    Pick a mining stock, any mining stock, and there’s a very good chance that its future earnings are highly dependent on commodity prices. Rio Tinto (RIO) and Vale (VALE)? That’s iron ore. Freeport McMoRan Copper & Gold (FCX)? That’s copper. Alcoa (AA)? That’s aluminum.

  • [By Frida Ghitis]

    At the same time, OROCF bought Borax Argentina from Rio Tinto (RIO) and now produces boric acid in Jujuy and Salta provinces (northern Argentina). It also has other lithium projects, but Olaroz is the key. The Australian management says first production will start by the end of the first half of this year.

Top 5 Prefered Companies To Invest In 2014: Societe Generale (GLE)

Societe Generale SA is a financial services company. The Company offers advisory and other services to individual customers, companies and institutions. The Company operates in five divisions: French Networks, International Retail Banking, Corporate and Investment Banking, Specialised Financial Services and Insurance, and Private Banking, Global Investment Management and Services. It operates Retail Banking in France under the Societe Generale, Credit du Nord and Boursorama brands. Its International Retail Banking is present in Central and Eastern Europe, Russia, the Mediterranean Basin, Sub-Saharan Africa, Asia and in the French Overseas territories. Private Banking, Global Investment Management and Services consist of four activities: Private Banking, Asset Management, Societe Generale Securities Services and Brokers. Advisors’ Opinion:

  • [By Alexis Xydias]

    Banks led the rally over the past four months, with Paris-based Societe Generale SA (GLE) and UniCredit SpA (UCG), Italy’s biggest lender, surging more than 45 percent.

  • [By Ruth David]

    Block sales in western Europe reached $31.8 billion in the three months through September as Groupama SA sold shares in Societe Generale (GLE) SA and Sweden exited a stake in Nordea Bank (NDA) AB, data compiled by Bloomberg show. At the same time, investors poured about $22.2 billion into the region’s stock funds in the 15 weeks through Oct. 9, according to data from research firm EPFR Global Inc.

  • [By Sarah Jones]

    HSBC, Europe’s biggest bank, Societe Generale SA (GLE), France’s second-largest lender, and Germany’s Commerzbank AG each climbed at least 2.6 percent after posting results. Allianz gained 3.6 percent after Europe’s largest insurer reported a jump in profit. Alstom SA (ALO) sank 12 percent after the power-equipment maker cut its profit forecast.

  • [By Namitha Jagadeesh]

    Societe Generale SA (GLE), France’s second-largest bank, advanced 1.4 percent to 31.03 euros as Goldman Sachs Group Inc. analysts recommended investors buy the shares, citing the firm’s improved funding levels.

Top 5 Prefered Companies To Invest In 2014: Inovio Pharmaceuticals Inc (INO)

Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company’s SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company’s electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators incl ude University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int’l.

Inovio’s Solution

The Company’s synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company’s synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deo xyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company’s synthetic vaccines are designed to generate specific antibody and/or T-cell responses.

The Company’s SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.

Cancer Synthetic Vaccines

The Company has two broad types of cancer vaccines : preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body’s natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.

Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females’ a ges 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.

Inovio’s VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).

In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.

Infectious Disease Synthetic Vaccines

In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio’s PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.

The Company’s VGX-3400X targe ts H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season’s new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.

Animal Health/Veterinary

VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.

The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Inovio Pharmaceuticals (NYSE: INO) was also up, gaining 10.53 percent to $3.57 after the company received the “Best Theraputic Vaccine” award at the World Vaccine Congress after the close Wednesday.

  • [By MONEYMORNING]

    Inovio Zooms: We recommended biotech Inovio Inc. (NYSE: INO) at 71 cents a share back on Feb. 1, 2013, and have re-recommended it a number of times since. With their 15.2% gain yesterday, the shares are now at $3.71, up 414% from where we first told you about them – and we believe there’s more to come. In fact, we’ll be bringing you an interesting update on this company very soon. Inovio is one of 24 recommendations that have doubled or better since we launched Private Briefing back in August 2011

  • [By Jake L’Ecuyer]

    Equities Trading DOWN
    Shares of Inovio Pharmaceuticals (NYSE: INO) were down on Friday’s session, falling 13.28 percent to $2.488 despite seemingly little news on the company.